Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods

Hua Lin Kao, Yi Chen Yeh, Chin Hsuan Lin, Wei Fang Hsu, Wen Yu Hsieh, Hsiang Ling Ho, Teh Ying Chou

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives Analysis of the targetable driver mutations is now recommended in all patients with advanced lung adenocarcinoma. Molecular-based methods are usually adopted, however, along with the implementation of highly sensitive and/or mutation-specific antibodies, immunohistochemistry (IHC) has been considered an alternative method for identifying driver mutations in lung adenocarcinomas. Materials and methods A total of 205 lung adenocarcinomas were examined for EGFR mutations and ALK and ROS1 rearrangements using real-time PCR, fluorescence in situ hybridization (FISH) and IHC in parallel. The performance of different commercially available IHC antibody clones toward targetable driver mutations was evaluated. The association between these driver mutations and clinicopathological characteristics was also analyzed. Results In 205 cases we studied, 58.5% were found to harbor EGFR mutations, 6.3% ALK rearrangements and 1.0% ROS1 rearrangements. Compared to molecular-based methods, IHC of EGFR mutations showed an excellent specificity but the sensitivity is suboptimal, while IHC of ALK and ROS1 rearrangements demonstrated high sensitivity and specificity. No significant difference regarding the performance of different antibody clones toward these driver mutations was observed, except that clone SP125 showed a higher sensitivity than 43B2 in the detection of p.L858R of EGFR. Conclusion In circumstances such as poor quality of nucleic acids or low content of tumor cells, IHC of EGFR mutation-specific antibodies could be used as an alternative method. Patients negative for EGFR mutations are subjected to further analysis on ALK and ROS1 rearrangements using IHC methods. Herein, we proposed a lung adenocarcinoma testing algorithm for the application of IHC in therapeutic diagnosis.

Original languageEnglish
Pages (from-to)40-47
Number of pages8
JournalLung Cancer
Volume101
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

Fluorescence In Situ Hybridization
Real-Time Polymerase Chain Reaction
Immunohistochemistry
Mutation
Antibodies
Clone Cells
Adenocarcinoma of lung
Sensitivity and Specificity
Nucleic Acids

Keywords

  • Driver mutations
  • Immunohistochemistry
  • Lung adenocarcinoma
  • Molecular testing

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas : Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods. / Kao, Hua Lin; Yeh, Yi Chen; Lin, Chin Hsuan; Hsu, Wei Fang; Hsieh, Wen Yu; Ho, Hsiang Ling; Chou, Teh Ying.

In: Lung Cancer, Vol. 101, 01.11.2016, p. 40-47.

Research output: Contribution to journalArticle

@article{20cda5928bb845ef911164b022a0bb7b,
title = "Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods",
abstract = "Objectives Analysis of the targetable driver mutations is now recommended in all patients with advanced lung adenocarcinoma. Molecular-based methods are usually adopted, however, along with the implementation of highly sensitive and/or mutation-specific antibodies, immunohistochemistry (IHC) has been considered an alternative method for identifying driver mutations in lung adenocarcinomas. Materials and methods A total of 205 lung adenocarcinomas were examined for EGFR mutations and ALK and ROS1 rearrangements using real-time PCR, fluorescence in situ hybridization (FISH) and IHC in parallel. The performance of different commercially available IHC antibody clones toward targetable driver mutations was evaluated. The association between these driver mutations and clinicopathological characteristics was also analyzed. Results In 205 cases we studied, 58.5{\%} were found to harbor EGFR mutations, 6.3{\%} ALK rearrangements and 1.0{\%} ROS1 rearrangements. Compared to molecular-based methods, IHC of EGFR mutations showed an excellent specificity but the sensitivity is suboptimal, while IHC of ALK and ROS1 rearrangements demonstrated high sensitivity and specificity. No significant difference regarding the performance of different antibody clones toward these driver mutations was observed, except that clone SP125 showed a higher sensitivity than 43B2 in the detection of p.L858R of EGFR. Conclusion In circumstances such as poor quality of nucleic acids or low content of tumor cells, IHC of EGFR mutation-specific antibodies could be used as an alternative method. Patients negative for EGFR mutations are subjected to further analysis on ALK and ROS1 rearrangements using IHC methods. Herein, we proposed a lung adenocarcinoma testing algorithm for the application of IHC in therapeutic diagnosis.",
keywords = "Driver mutations, Immunohistochemistry, Lung adenocarcinoma, Molecular testing",
author = "Kao, {Hua Lin} and Yeh, {Yi Chen} and Lin, {Chin Hsuan} and Hsu, {Wei Fang} and Hsieh, {Wen Yu} and Ho, {Hsiang Ling} and Chou, {Teh Ying}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.lungcan.2016.09.007",
language = "English",
volume = "101",
pages = "40--47",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas

T2 - Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods

AU - Kao, Hua Lin

AU - Yeh, Yi Chen

AU - Lin, Chin Hsuan

AU - Hsu, Wei Fang

AU - Hsieh, Wen Yu

AU - Ho, Hsiang Ling

AU - Chou, Teh Ying

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objectives Analysis of the targetable driver mutations is now recommended in all patients with advanced lung adenocarcinoma. Molecular-based methods are usually adopted, however, along with the implementation of highly sensitive and/or mutation-specific antibodies, immunohistochemistry (IHC) has been considered an alternative method for identifying driver mutations in lung adenocarcinomas. Materials and methods A total of 205 lung adenocarcinomas were examined for EGFR mutations and ALK and ROS1 rearrangements using real-time PCR, fluorescence in situ hybridization (FISH) and IHC in parallel. The performance of different commercially available IHC antibody clones toward targetable driver mutations was evaluated. The association between these driver mutations and clinicopathological characteristics was also analyzed. Results In 205 cases we studied, 58.5% were found to harbor EGFR mutations, 6.3% ALK rearrangements and 1.0% ROS1 rearrangements. Compared to molecular-based methods, IHC of EGFR mutations showed an excellent specificity but the sensitivity is suboptimal, while IHC of ALK and ROS1 rearrangements demonstrated high sensitivity and specificity. No significant difference regarding the performance of different antibody clones toward these driver mutations was observed, except that clone SP125 showed a higher sensitivity than 43B2 in the detection of p.L858R of EGFR. Conclusion In circumstances such as poor quality of nucleic acids or low content of tumor cells, IHC of EGFR mutation-specific antibodies could be used as an alternative method. Patients negative for EGFR mutations are subjected to further analysis on ALK and ROS1 rearrangements using IHC methods. Herein, we proposed a lung adenocarcinoma testing algorithm for the application of IHC in therapeutic diagnosis.

AB - Objectives Analysis of the targetable driver mutations is now recommended in all patients with advanced lung adenocarcinoma. Molecular-based methods are usually adopted, however, along with the implementation of highly sensitive and/or mutation-specific antibodies, immunohistochemistry (IHC) has been considered an alternative method for identifying driver mutations in lung adenocarcinomas. Materials and methods A total of 205 lung adenocarcinomas were examined for EGFR mutations and ALK and ROS1 rearrangements using real-time PCR, fluorescence in situ hybridization (FISH) and IHC in parallel. The performance of different commercially available IHC antibody clones toward targetable driver mutations was evaluated. The association between these driver mutations and clinicopathological characteristics was also analyzed. Results In 205 cases we studied, 58.5% were found to harbor EGFR mutations, 6.3% ALK rearrangements and 1.0% ROS1 rearrangements. Compared to molecular-based methods, IHC of EGFR mutations showed an excellent specificity but the sensitivity is suboptimal, while IHC of ALK and ROS1 rearrangements demonstrated high sensitivity and specificity. No significant difference regarding the performance of different antibody clones toward these driver mutations was observed, except that clone SP125 showed a higher sensitivity than 43B2 in the detection of p.L858R of EGFR. Conclusion In circumstances such as poor quality of nucleic acids or low content of tumor cells, IHC of EGFR mutation-specific antibodies could be used as an alternative method. Patients negative for EGFR mutations are subjected to further analysis on ALK and ROS1 rearrangements using IHC methods. Herein, we proposed a lung adenocarcinoma testing algorithm for the application of IHC in therapeutic diagnosis.

KW - Driver mutations

KW - Immunohistochemistry

KW - Lung adenocarcinoma

KW - Molecular testing

UR - http://www.scopus.com/inward/record.url?scp=84988025920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988025920&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2016.09.007

DO - 10.1016/j.lungcan.2016.09.007

M3 - Article

C2 - 27794407

AN - SCOPUS:84988025920

VL - 101

SP - 40

EP - 47

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -